1. Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling

   • Ben-Fillippo Krippendorff
   • Diego A. Oyarzún
   • Wilhelm Huisinga

   Original Paper Open access 08 March 2012 Pages: 125 - 139

   

2. Dose correction for the Michaelis–Menten approximation of the target-mediated drug disposition model

   • Xiaoyu Yan
   • Wojciech Krzyzanski

   OriginalPaper 04 January 2012 Pages: 141 - 146

   

3. Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

   • Kerenaftali Klein
   • Ivelina Gueorguieva
   • Leon Aarons

   Original Paper 21 January 2012 Pages: 147 - 160

   

4. Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis

   • Holly Kimko
   • Ekaterina Gibiansky
   • Frank Wiegand

   Original Paper 22 January 2012 Pages: 161 - 176

   

5. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis

   • B. D. Lacroix
   • L. E. Friberg
   • M. O. Karlsson

   Original Paper 21 January 2012 Pages: 177 - 193

   

6. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

   • Ashley Strougo
   • Thomas Eissing
   • Jan Freijer

   Original Paper Open access 05 February 2012 Pages: 195 - 203

   

7. Moxifloxacin versus placebo modeling of the QT interval

   • Philippe Grosjean
   • Saïk Urien

   Original Paper 17 February 2012 Pages: 205 - 215

   

8. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model

   • Yan Xin
   • Hong Xiang
   • Shuang Bai

   Original Paper 01 March 2012 Pages: 217 - 226